Imatinib Aenorasis

Imatinib, the active ingredient in Imatinib Aenorasis, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients.\\n\\nGNH India supplies Imatinib Aenorasis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Imatinib targets specific tyrosine‑kinase driven cancers and is used in several approved indications.\\n\\nChronic myeloid leukemia (CML): improves survival by inhibiting the BCR‑ABL fusion protein that drives leukemic proliferation.\\nGastrointestinal stromal tumor (GIST): reduces tumor growth by blocking c‑KIT and PDGFR signaling pathways.\\nPhiladelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): provides targeted therapy that suppresses leukemic cell expansion.

Adverse reactions may vary in frequency and severity.\\n\\nCommon Side Effects:\\n- Nausea or vomiting\\n- Edema, especially peripheral\\n- Muscle cramps or pain\\n- Fatigue or weakness\\n- Diarrhoea\\n- Skin rash or pruritus\\n\\nSerious or Rare Side Effects:\\n- Neutropenia or severe leukopenia\\n- Hepatotoxicity with elevated transaminases\\n- Cardiac failure or reduced left‑ventricular function\\n- Severe bleeding events\\n- Interstitial lung disease or pneumonitis\\n- Stevens‑Johnson syndrome or toxic epidermal necrolysis

Patients should be monitored closely for safety concerns before and during therapy.\\n\\nMonitor blood counts: watch for neutropenia and anemia.\\nAssess liver function: check transaminases regularly.\\nEvaluate cardiac status: baseline and periodic echocardiograms are advised.\\nAvoid in patients with known hypersensitivity to imatinib or its excipients.\\nUse caution in renal impairment: dose adjustment may be required.\\nStore at ambient temperature: keep in the original pack, protect from moisture.

Imatinib may interact with other medicines that affect its metabolism or pharmacodynamics.\\n\\nMajor Interactions (Avoid):\\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can raise imatinib plasma levels and increase toxicity.\\n- Potent CYP3A4 inducers (e.g., rifampicin, carbamazepine): may lower imatinib exposure and reduce efficacy.\\n\\nModerate Interactions (Monitor Closely):\\n- Proton pump inhibitors (e.g., omeprazole): may modestly affect absorption; monitor therapeutic response.\\n- Anticoagulants (e.g., warfarin): imatinib can alter INR; check coagulation parameters regularly.\\n- Vaccines containing live attenuated virus: immunosuppression may reduce vaccine effectiveness; consider timing.